Cargando…
Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is an aggressive and the most common type of non-Hodgkin lymphoma (NHL). The clinical use of rituximab has improved the treatment response and survival of patients with DLBCL. The introduction of rituximab biosimilar into healthcare system has helped...
Autores principales: | Nair, Reena, Bhat, Gull Mohammad, Agrawal, Narendra, Sengar, Manju, Malhotra, Pankaj, Nityanand, Soniya, Lele, Chitra, Reddy, Pramod, Kankanwadi, Suresh, Maharaj, Narendra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580068/ https://www.ncbi.nlm.nih.gov/pubmed/37854680 http://dx.doi.org/10.3389/fonc.2023.1248723 |
Ejemplares similares
-
Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis
por: Roy, Partha Sarathi, et al.
Publicado: (2013) -
Summary of the published Indian data on chronic myeloid leukemia
por: Singhal, Manish K., et al.
Publicado: (2016) -
Therapeutic drug monitoring for imatinib: Current status and Indian experience
por: Arora, Brijesh, et al.
Publicado: (2013) -
Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
por: Svensson, Robin J., et al.
Publicado: (2022) -
Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015)